Guizhou Sanli Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceuticals. The products primarily include respiratory medications, tonics, gynecological medications, orthopedic medications, and cardiovascular medications. The specific pharmaceutical products include Kaihoujian Spray (children's version), Kaihoujian Spray, Qijiao Shengbai Capsules, Fuke Zaizao Pills, Zhike Huatan Pills, Huangqi Granules, and Qiangli Tianma Duzhong Capsules. The Company distributes its products within the domestic market.

Employees

1,887

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26/06/26	CN¥13.24	-5.36%	12,592,200
25/06/26	CN¥13.99	-4.96%	14,323,300
24/06/26	CN¥14.72	-0.88%	13,854,000
23/06/26	CN¥14.85	-3.76%	17,286,900
22/06/26	CN¥15.43	-1.34%	17,833,200

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 26/06/2026			5-day change	1st Jan Change
13.24 ^CNY	-5.36%		-15.35%	+13.16%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE

Market Cap	5.36B 788M 691M 637M 596M 1.12B 74.31B 1.14B 7.65B 2.96B 36.73B 2.96B 2.89B 127B	P/E 2024	19.4x	P/E 2025	106x
Enterprise Value	5.71B 839M 736M 678M 635M 1.19B 79.15B 1.22B 8.15B 3.15B 39.12B 3.15B 3.08B 136B	EV / Sales 2024	2.48x	EV / Sales 2025	2.99x
Free-Float	40.74%	Yield 2024	2.62%	Yield 2025	0.51%

05-26	Guizhou Sanli Pharmaceutical to Raise Up to 700 Million Yuan in Private Placement	MT
05-25	Guizhou Sanli pharmaceutical to raise funds via private placement	RE
05-25	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 700 million in funding	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-26	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Guizhou Sanli Pharmaceutical Co.,Ltd announced that it expects to receive CNY 300 million in funding	CI
12-03	Sanli Pharma to Withdraw Stake in Associate; Shares Down 3%	MT
27/10/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
12/09/25	Tranche Update on Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on September 13, 2024.	CI
11/09/25	Guizhou Sanli Pharmaceutical Co.,Ltd's Equity Buyback announced on September 12, 2024, has closed with 7,869,300 shares, representing 1.93% for CNY 99.95 million.	CI
27/08/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
23/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd announces Annual dividend, payable on June 26, 2025	CI
22/04/25	Guizhou Sanli Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	-5.36%
1 week	-15.35%
Current month	-18.67%
1 month	-10.30%
3 months	+22.59%
6 months	+11.54%
Current year	+13.16%

GuiZhou SanLi Pharmaceutical Co.,Ltd Stock

Stocks

603439

CNE1000040B4

Pharmaceuticals

Valuation: GuiZhou SanLi Pharmaceutical Co.,Ltd

Chart: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest news : GuiZhou SanLi Pharmaceutical Co.,Ltd

Quotes and Performance

Course Extremes

Managers and Directors: GuiZhou SanLi Pharmaceutical Co.,Ltd

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	13.2	16.25
1 month	13.2	17.46
Current year	10.49	17.46
1 year	10.49	17.46
3 years	10.49	20.34
5 years	10.49	21.28
10 years	8.82	44.1

Manager	Title	Age	Since
Qian Fan Zhang CEO	Chief Executive Officer	41	27/05/2024
Hai Zhang CEO	Chief Executive Officer	41	01/09/2011
Ke Guo DFI	Director of Finance/CFO	39	01/11/2024

Director	Title	Age	Since
Shi Gui Chen BRD	Director/Board Member	63	12/12/2022
Wei Sheng Feng BRD	Director/Board Member	66	10/10/2024
Hai Zhang CHM	Chairman	41	01/03/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/09/24	Hai Zhang	Sell	Chief Executive Officer	21,000,000	5.1428%
02/08/24	Jue Ben Wang	Buy	Director	13,000	0.0032%
05/08/23	Yuan Yu	Sell		25,000	0.0061%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU SANLI PHARMACEUTICAL CO.,LTD	-5.36%	-15.35%	+10.52%	-19.71%	833M
ELI LILLY AND COMPANY	+6.60%	+8.75%	+50.73%	+164.71%	1,006B
JOHNSON & JOHNSON	+3.42%	+9.33%	+66.36%	+54.54%	589B
ABBVIE INC.	+1.68%	+7.44%	+32.30%	+83.12%	430B
ROCHE HOLDING AG	-0.66%	+5.11%	+29.26%	+21.27%	331B
ASTRAZENECA PLC	+1.82%	+8.19%	+41.15%	+26.80%	288B
NOVARTIS AG	+0.22%	+6.75%	+31.51%	+42.02%	285B
NOVO NORDISK A/S	+0.73%	+8.53%	-26.22%	-40.85%	213B
AMGEN INC.	+1.53%	+3.88%	+28.29%	+59.34%	190B
GILEAD SCIENCES, INC.	+1.73%	+0.73%	+16.88%	+64.30%	154B
Average	+1.06%	+3.94%	+28.08%	+45.55%	348.66B
Weighted average by Cap.	+2.89%	+5.37%	+39.27%	+78.21%

	2024	2025
Net sales	2.14B 315M 276M 255M 239M 447M 29.74B 457M 3.06B 1.18B 14.7B 1.18B 1.16B 50.96B	1.7B 250M 219M 202M 189M 355M 23.61B 363M 2.43B 941M 11.67B 940M 919M 40.47B
Net income	274M 40.28M 35.32M 32.56M 30.48M 57.16M 3.8B 58.34M 391M 151M 1.88B 151M 148M 6.51B	46.25M 6.8M 5.96M 5.5M 5.14M 9.65M 641M 9.85M 66.05M 25.56M 317M 25.53M 24.97M 1.1B
Net Debt	108M 15.83M 13.88M 12.79M 11.98M 22.46M 1.49B 22.92M 154M 59.49M 738M 59.43M 58.13M 2.56B	349M 51.26M 44.95M 41.43M 38.79M 72.73M 4.84B 74.24M 498M 193M 2.39B 192M 188M 8.29B